WHAT IS CLAIMED IS:

ĺ	1.	A composition for facilitating delivery of a nucleic acid catalyst to
2	a biological system, s	said composition comprising a polyethylene glycol (PEG)-ceramide
3	conjugate, a lipid and	I said nucleic acid catalyst in proportions sufficient to achieve said
4	delivery of said nucle	eic acid catalyst to said biological system.
	·	
1	2.	The composition of claim 1 further comprising phosphatidyl
2	choline.	
	3.	The composition of claim 1 further comprising cholesterol.
1	4.	The composition of claim 1 further comprising phosphatidyl choline
2[]	and cholesterol.	
	5.	The composition of claims 1, 2, 3 or 4, wherein said nucleic acid
2	catalyst has an endor	nuclease activity.
1.5	6.	The composition of claim 5, wherein said nucleic acid catalyst
211	comprises one or mo	ore ribonucleotides.
1	7.	The composition of claim 5, wherein said nucleic acid catalyst
2	comprises one or mo	ore deoxyribonucleotides.
1	8.	The composition of claim 5, wherein said nucleic acid catalyst is ir
2	a hammerhead motif	· .
1	9.	The composition of claims 1, 2, 3 or 4, wherein said lipid is a
2	cationic lipid.	
1	10.	The composition of claims 1, 2, 3 or 4, wherein said lipid is
2	N,N-dioleyl-N,N-di	methylammonium chloride (DODAC).

				\ 42
1			11.	The composition of claims 1, 2, 3 or 4, wherein said lipid is
2		1,2-dioleoylo	xy-3(N,	N,N-trimethylamino) propane chloride (DOTAP).
1			12.	The composition of claims 1, 2, 3 or 4, wherein said
2		PEG-Ceramid	le conju	gate comprises a fatty acid group having eight carbon atoms.
1			13.	The composition of claims 1, 2, 3 or 4, wherein said
2		PEG-Ceramid	le conju	gate comprises a fatty acid group having fourteen carbon atoms.
			- 4	
1			14.	The composition of claims 1, 2, 3 or 4, wherein said
2		PEG-Ceramic	le conju	igate comprises a fatty acid group having twenty carbon atoms.
	H. That. O. U.		1 =	The second state of slains 2 and whomin gold phombatidad
1		1 1	15.	The composition of claims 2 or 4, wherein said phosphatidyl
2		choline is egg	д уогк р	phosphatidyl chorine.
1	Annie (1986 - 1980) and Annie (1986) and		16.	A pharmaceutical composition comprising the composition of
2		claims 1 2 3		and a pharmaceutically or veterinarially acceptable carrier.
_	1.1 1.1	Ciamiis 1, 2,	5 01 4 0	ma a pharmacourteany or votormariary accoptance current
1	And the first than the first that the first than th		17.	A mammalian cell comprising the composition of claims 1, 2, 3 or
2		4.		
_				
1			18.	The mammalian cell of claim 17, wherein said mammalian cell is a
2		human cell.		
1			19.	A mammalian cell comprising the pharmaceutical composition of
2		claim 16.		
1			20.	The mammalian cell of claim 19, wherein said mammalian cell is a
2		human cell.		
1			21.	The composition of claims 1/2, 3 or 4, wherein said nucleic acid
2		catalyst is ca	pable of	f decreasing the expression of RNA associated with a mammalian
3		disease.		

22.	The composition of claim 21, wherein said mammalian disease is a
human disease.	
23.	The composition of claim 21, wherein said disease is cancer.
24.	The composition of claim 21, wherein said disease is inflammation.
25.	A pharmaceutical composition comprising the composition of claim
21 and a pharmaceu	tically or veterinarially acceptable carrier.
26.	A method of facilitating the transfer of a nucleic acid catalyst into a
cell, said method co	omprising contacting said cell with the composition of claims 1, 2, 3
or 4 under condition	ns suitable for the transfer of said nucleic acid catalyst into said
biological system.	
27.	A method of treatment of a disease in a patient, said method
comprising administ	tering to said patient the pharmaceutical composition of claim 25
under conditions in	which the expression the RNA associated with said disease is
decreased in said pa	tient and a therapeutic result is attained.
28.	The method of claim 27, wherein said disease is cancer.
29.	The method of claim 27, wherein said disease is inflammation.
30.	The method of claim 27, wherein said administration is a systemic
administration.	
31.	A method of treatment of a disease in a patient comprising the step
of administering to	said patient the composition of claim 21 under conditions in which
the expression the F	RNA associated with said disease is decreased in said patient and a
therapeutic result is	attained.
32.	The method of claim 31, wherein said disease is cancer.

	1
1	33. The method of claim 31, wherein said disease is inflammation.
1	34. The method of claim 31, wherein said administration is a systemic
2	administration.
1	35. The composition of claims 1, 2, 3 or 4, wherein said nucleic acid
2	catalyst is chemically modified.
1	36. The composition of claim 5, wherein said nucleic acid catalyst
2	specifically cleaves RNA encoded by vascular endothelial growth factor receptor (VEGF-
3	R) RNA.
4,1,14 11,12 11,13	
ļ. M	37. The composition of claim 36, wherein said nucleic acid catalyst is
	VEGF-R-1.
	20 Till I am sixting of plains 16 forther communicing
	38. The pharmaceutical composition of claim 16 further comprising
	pharmaceutically acceptable fillers, adjuvants and diluents.
	39. A method of cleaving a merger nucleic acid molecule in a cell, said
#J	method comprising contacting said cell with the composition of claim 5 under conditions
1 1	suitable for the cleavage of said merger nucleic acid molecule.
3	Suitable for the cicavage or said morger indicate and morecure.
1	40. The composition of claims 1, 2, 3 or 4, wherein said composition
2	is formed by the reverse phase evaporation process.
2	is formed by the reverse plants of the
1	41. The composition of claims 1, 2, 3 or 4, wherein said composition
2	is formed by the Bligh and Dyer extraction method.
1	42. The composition of claims 1, 2, 3 or 4, wherein the concentration
2	of said lipid is between 0-30 percent.
1	43. The composition according to claim 42, wherein the concentration
2	of said lipid is between 5-30 percent.

	, 45
1	44. The composition of claim 43, wherein the concentration of said
2	lipid is 15 percent.
1	45. The composition of claim 15, wherein the concentration of said egg
2	yolk phosphatidyl choline is 50 percent, the concentration of said cholesterol is 25
3	percent, the concentration of said lipid is 15 percent and the concentration of said
4	PEG-Ceramide conjugate is 10 percent.
1	46. The composition of claims 1, 2, 3 or 4, wherein said nucleic acid
2	catalyst is represented by a plasmid expression vector encoding said nucleic acid catalyst
3	ia a manner that allows expression of said nucleic acid catalyst in said biological system.
1 1.5	47. The composition of claims 1, 2, 3 or 4, wherein said biological
1 2	system is a tumor.
1 15	48. The composition of claims 1, 2, 3 or 4, wherein said biological
2 ************************************	system is a mammalian eye.
1 1,5	49. The composition of claims 1, 2, 3 or 4, wherein said
2 11	PEG-Ceramide conjugate comprises a fatty acid group having between six and twenty
3	carbon atoms.
1	50. A composition for facilitating delivery of a nucleic acid catalyst to
2	a biological system, said method comprising a polyethylene glycol (PEG)-ceramide
3	conjugate, phosphatidylcholine, cholesterol and said nucleic acid catalyst in proportions
4	sufficient to achieve said delivery of the nucleic acid catalyst to said biological system.
1	51. The composition of claim 50, wherein said nucleic acid catalyst has
2	an endonuclease activity.
1	52. The composition of claim 50, wherein said nucleic acid catalyst
2	comprises one or more ribonucleotides.

1	53.	The composition of claim 50, wherein said nucleic acid catalyst
2	comprises one or mo	ore deoxyribonucleotides.
1	54.	The composition of claim 50, wherein said nucleic acid catalyst is
2	in a hammerhead mo	\
_		
1	55.	The composition of claim 50, wherein said PEG-Ceramide
2	conjugate comprises	a fatty acid group having between six and twenty carbon atoms.
1	56.	The composition of clam 55, wherein said PEG-Ceramide conjugate
2	comprises a fatty aci	d group having eight carbon atoms.
₩. }	57.	The composition of claim 55, wherein said PEG-Ceramide
11J 21	conjugate comprises	a fatty acid group having fourteen carbon atoms.
	3 0 1	
Fig. 7. Can Star Star Star Star Star Star Star Star	58.	The composition of claim 55, wherein said PEG-Ceramide
2 -	conjugate comprises	a fatty acid group having twenty carbon atoms.
14.1 14.1	3 0 1	
	59.	The composition of claim 50, wherein said phosphatidyl choline is
2	egg yolk phosphatidy	
₹₽₫		
1	60.	A pharmaceutical composition comprising the composition of claim
2		ically or veterinarially acceptable carrier.
	F	
1	61.	A composition for facilitating the delivery of a nucleic acid catalyst
2	to a biological system	n, said composition comprising a non-cationic lipid, a cationic lipid,
3		-ceramide (PEG-Cer) conjugate and said nucleic acid catalyst in
4		t to achieve the delivery of said nucleic acid catalyst to said
5	biological system.	a so define to the derivery of said indefere deld catalyst to said
	- ·	1
	10000	•
	$(\mathcal{A}\mathcal{A}\mathcal{A}\mathcal{A}\mathcal{O})$	

add si